Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Santa Fe Petroleum, Inc.Financial_Report.xls
EX-32.1 - EXHIBIT 32.1 - Santa Fe Petroleum, Inc.v305534_ex32-1.htm
EX-31.1 - EXHIBIT 31.1 - Santa Fe Petroleum, Inc.v305534_ex31-1.htm
EX-31.2 - EXHIBIT 31.2 - Santa Fe Petroleum, Inc.v305534_ex31-2.htm
EX-32.2 - EXHIBIT 32.2 - Santa Fe Petroleum, Inc.v305534_ex32-2.htm

 

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES

EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2011

 

Commission File Number: _________

 

BABY ALL CORP

(Exact name of small business issuer as specified in its charter)

 

Delaware   99-0362658
     
(State of incorporation)   (IRS Employer ID Number)

  

c/o Efrat Schwartz

17 HaRav Frank Street

Jerusalem 96387, Israel

Phone number: 972-2-6415-008

Fax number: 972-2-6415-008

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

None

 

Securities registered pursuant to Section 12(g) of the Exchange Act:

Common Stock, $0.0001 par value

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes   ¨       No   x

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes   ¨      No   x

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x    No ¨

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.     ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer    ¨   Accelerated filer   ¨
Non-accelerated filer     ¨   Smaller reporting company    x
(Do not check if a smaller reporting company)    

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes   £ No  x

 

The number of shares of the issuer’s common stock issued and outstanding as of March 22, 2012, was 5,500,000 shares.

 

The Company’s Common Stock is currently not yet trading on the public markets

 

Documents Incorporated By Reference:  None

 

 
 

 

TABLE OF CONTENTS

 

        Page
PART I       3
Item 1   Business   3
Item 1A   Risk Factors   5
Item 1B   Unresolved Staff Comments   6
Item 2   Properties   6
Item 3   Legal Proceedings   6
         
PART II       6
Item 4   Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   6
Item 5   Selected Financial Data   7
Item 6   Management’s Discussion and Analysis of Financial Condition and Results of Operation   7
Item 6A   Quantitative and Qualitative Disclosures About Market Risk.   11
Item 7   Financial Statements and Supplementary Data   F-1
Item 8   Changes in and Disagreements With Accountants on Accounting and Financial Disclosure   12
Item 8A(T)   Controls and Procedures   12
Item 8B   Other Information   13
         
PART III       14
Item 9   Directors, Executive Officers and Corporate Governance   14
Item 10   Executive Compensation   16
Item 11   Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   16
Item 12   Certain Relationships and Related Transactions, and Director Independence   17
Item 13   Principal Accountant Fees and Services   18
         
PART IV       18
Item 14   Exhibits and Financial Statement Schedules   18
SIGNATURES       19

 

2
 

 

PART I

 

Item 1.  Business.

 

As used in this Annual Report on Form 10-K (this “Report”), references to the “Company,” the “Registrant,” “we,” “our,” “us” or “Baby All Corp” , unless the context otherwise indicates .

 

Forward-Looking Statements

 

This Report contains forward-looking statements. For this purpose, any statements contained in this Report that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking information includes statements relating to future actions, prospective products, future performance or results of current or anticipated products, sales and marketing efforts, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management, and other matters. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “will,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “continue” or the negative of these similar terms. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking information to encourage companies to provide prospective information about themselves without fear of litigation so long as that information is identified as forward-looking and is accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in the information.

 

These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that we cannot predict. In evaluating these forward-looking statements, you should consider various factors, including the following: (a) those risks and uncertainties related to general economic conditions, (b) whether we are able to manage our planned growth efficiently and operate profitable operations, (c) whether we are able to generate sufficient revenues or obtain financing to sustain and grow our operations, (d) whether we are able to successfully fulfill our primary requirements for cash, which are explained below under “Liquidity and Capital Resources.” We assume no obligation to update forward-looking statements, except as otherwise required under the applicable federal securities laws.

 

Corporate Background

 

We were incorporated in Delaware on November 30, 2010 and are a development stage company. On December 13, 2010, we entered into an exclusive worldwide patent sale agreement (the “Design Patent Transfer and Sale Agreement “) with Mrs. Julie Franchi, the inventor and seller of the patent, in relation to the sale and transfer of United States Design Patent Number 380828 for an infant medicine dispenser (the “Patent’). The technology that is the subject of the Patent has the potential to provide an additional way in which infants are given medicine and potentially liquid vitamins and other liquids in small quantities.  Baby All Corp. purchased the Patent from  Mrs. Julie Franchi , the inventor, in exchange for a payment to Mrs. Franchi of US $5,000 (five thousand United States Dollars), according to the conditions specified in the Design Patent Transfer and Sale Agreement.  There is no relationship between Mrs. Franchi, the seller, and Baby All Corp., its directors, or its affiliates. We do not know whether Mrs. Franchi has any experience in developing patents or in developing products based on or embodying her inventions. The seller was not able to commercialize the product due to a lack of funds. The seller did not build a prototype and a working prototype has not been built since we purchased rights to the patent and hence no testing has been done to determine the ability of the technology to perform as we expect, its reliability, or its cost effectiveness.

 

The patented invention that Baby All Corp. purchased from Mrs. Franchi is based on a design patent for an infant medicine dispenser with measurements on the side to enable someone to easily measure the appropriate amount to dispense. The top of the dispenser is similar to an infant bottle, enabling a child to easily suck the medicine out of the dispenser.

 

We were not involved in the design and patenting process for the patented technology, and we have not incurred any costs associated with the design and patenting of the technology.  The only costs we have incurred to date have been the costs associated with our acquisition of the Patent from the inventor, which amounted to $5,000 to purchase the Patent and $2,500 in related legal fees.  We plan to rely on third parties to develop, manufacture, and market our proposed product.  In this regard, we plan to license the patent to a third-party to design, manufacture, and market a product based on the Patent against an initial payment to us and a percentage royalty to be paid quarterly.

 

Business Summary

 

We were incorporated in Delaware on November 30, 2010 and are a development stage company. A Design Patent Transfer and Sale Agreement was signed between Mrs. Julie Franchi (the inventor and seller), in relation to a patented technology on December 13, 2010, granting Baby All Corp. exclusive rights, title and interest in and to the Design Patent Number: 380828 and all Intellectual Property rights, free and clear of any lien, charge, claim, preemptive rights, etc. for an infant medicine dispenser.

 

3
 

 

The seller of the Patent was not able to commercialize the product due to a lack of funds. The seller did not build a prototype and a working prototype has not been built since we purchased rights to the patent and hence no testing has been done to determine the ability of the technology to perform as we expect its reliability, or its cost effectiveness.

 

The patented invention is for a specially designed infant feeding-type bottle that allows parents and other care givers to administer liquid medications to infants in a more convenient and familiar structure. The Patent’s dispenser design specifies using a small plastic bottle similar in shape to a conventional baby bottle but of a much smaller size. The bottle design will be marked with measurement lines and corresponding dosage notations ranging from ¼ teaspoon to 2 teaspoons or 1cubic centimeter (cc) to 10, depending on manufacturing decisions and market preferences. According to the patent, the top of the infant medicine dispenser is fitted with a rubber nipple cap that is easily detachable to allow washing and reuse. This rubber cap would be held against the top of the bottle by a screw-on plastic ring mechanism that fits over the nipple cap and rests against the rubber lip at the bottom of the nipple.

 

The principal benefits offered by this design are convenience and familiarity. It is our belief that without a device such as this, it might be difficult to confirm whether or not the child ingested the appropriate quantity of the liquid medication being administered. One approach has been to use an eye dropper or similar device. This however, is less familiar to an infant than a standard bottle-type design and the child might push the eye dropper or other device away from its mouth. The feeling that this is not something known to the child, combined with what may be an unpleasant or unfamiliar taste associated with the medication, might trigger the child’s natural response to reject the medicine.

 

It is our belief that by using the patented infant medicine dispenser design, the potential problems of an unfamiliar object is reduced and, in its place, an object is used with which the child is familiar and with which positive attributes are associated. 

 

Even very young children, who are familiar to a standard bottle, will be comfortable with a bottle. For children who are exclusively breast-fed, it is possible that our design may not have any advantage over other products on the market.

 

While our patent design does offer benefits for children who are already familiar with being fed with standard bottles (including design and nipple formulation), our product is similar to all other infant medicine dispensers in regards that it will not alleviate the issue of a child having an adverse reaction to the unexpected taste of the medicine. However, we believe that the child’s negative reaction will be less when administered through a familiar design, such as our product.

 

It is our belief that this arrangement should result in more convenience for the parent or caregiver, as it allows them to carry a single dose of a child’s medication when travelling for a short period of time, rather than carrying the entire bottle of medication. Furthermore, our product makes giving children more convenient because the dose can be measured at any time, for example, while an infant is sleeping, and administered later when the child is awake. While a sick child may need more attention while it is awake, doctors prescribe a specific dose. Measuring this calmly and storing it in a convenient, already measured location, such as our product, means it can be given at the appropriate time, no matter where the child or caregiver is currently located. Since some medications, for example some antibiotics given to children for ear infections, requires refrigeration, it is better to only remove a single dose from the refrigerated container, leaving the container refrigerated, as per the instructions on the package, while traveling with a single non-refrigerated dose until it is time to administer it.

 

We have not had any actual testing to our patented technology.

 

Other products currently available on the market include devices shaped to please a child, but none are designed as our product. The market offerings include pacifier-type devices which would be strange for a child that is not accustomed to using a pacifier, or even, specifically, that type of pacifier. Further, there is a device shaped like an elephant. While this will entertain the child, it is not in a form to which the child is accustomed to seeing or putting in his or her mouth. While our research found a medical bottle which included a syringe inside of it in which the medicine is contained, we did not find any device similar to our patented design whereby the medicine is put directly into the device and not through a syringe. We believe that the inclusion of a syringe device inside a familiar bottle/nipple combination may complicate the process of administering the medication. While this process may lessen a child’s negative response to the foreign taste of the medication because the medicine is mixed with formula or some other liquid, it may also require the child to ingest a greater quantity of liquid. Also, it may complicate the cleaning process, requiring more attention from the caregiver at a time when the child may need more attention.

 

We believe the design of our device makes measuring and administering medication simple and effective because our product has the familiar shape and feel of a standard bottle and nipple, so even very young children are comfortable with the familiarity of the design. As we are interested in finding a third party partner to help us bring our product to the market, Baby All and its product do not yet have any position in the market.

 

While we believe children will feel comfortable with the familiarity of our product, which is similar to standard bottles used for drinking, there is the risk that caregivers may reject the need for our product, opting instead for traditional methods of administering medicine to their children.

 

4
 

 

Our infant medicine dispenser design was designed with a removable cover, which provides for the convenience of making a liquid medication portable for future use. This creates an easy-to-transport, compact medicine dispenser that saves space because parents and care givers no longer need to carry around the entire medicine container. With the removable cover, they can store one dose of the medicine in the medicine dispenser and then administer it at a later time. A possible limitation or disadvantage of this technology is that it exposes the medication to external temperatures if the user puts the medication in the Baby All product for long periods before administering. Because a syringe or eyedropper may leak, a typical user will carry both the medicine in the original container and also the dispenser separately. The removable cover prevents the spilling of the medication, encouraging the user to take one dose of the medication with them. Another limitation is that there is no mechanism to limit storing more than one dose in the Baby All device. If a doctor prescribes 5 mm., for example, and if the licensed third party partner manufactures the technology to hold 10 mm., it is possible that the user will actually include two doses. There is no mechanism to limit the intake of the medication if the user does not regulate this measurement himself or herself.

 

The design and development of a commercial product will be carried out by third party partners who agree to license the design and pay a portion of future royalties to maintain the license on an ongoing basis. We have not generated any revenues to date and our operations have been limited to organizational, start-up, and capital formation activities. We currently have no employees other than our Officers, who are also our Directors.

 

Due to our management’s inexperience we do not know the exact extent to which our product is subject to the Consumer Product Safety Improvement Act, the FDA approval process or other government regulations and are therefore unable to evaluate whether a potential third-party manufacturer or licensee may be exposed to penalties and sanctions for noncompliance. 

  

We have never declared bankruptcy, have never been in receivership, and have never been involved in any legal action or proceedings. We have not made any significant purchase or sale of assets, nor has the Company been involved in any mergers, acquisitions or consolidations. We are not a blank check registrant as that term is defined in Rule 419(a)(2) of Regulation C of the Securities Act of 1933, because we have a specific business plan and purpose. Neither Baby All Corp., nor its Officers, Directors, promoters or affiliates, has had preliminary contact or discussions with, nor do we have any present plans, proposals, arrangements or understandings with any representatives of the owners of any business or company regarding the possibility of an acquisition or merger.

  

Employees

 

Other than our current Directors and officers, we have two part-time employees..

 

Transfer Agent

 

We have engaged Nevada Agency and Trust as our stock transfer agent. Nevada Agency and Trust is located at 50 West Liberty Street, Reno, Nevada 89501. Their telephone number is (775) 322-0626 and their fax number is (775) 322-5623. The transfer agent is responsible for all record-keeping and administrative functions in connection with our issued and outstanding common stock.

 

Item 1A. Risk Factors

 

In addition to the risk factors described in our Registration Statement on Form S1, as filed with the Securities and Exchange Commission, and although smaller reporting companies are not required to provide disclosure pursuant to this Item, your attention is directed to the following risk factor that relates to our business.

 

5
 

 

We do not have sufficient cash to fund our operating expenses for the next twelve months, and plan to seek funding through the sale of our common stock. Without significant improvement in the capital markets, we may not be able to sell our common stock and funding may not be available for continued operations.

 

There is not enough cash on hand to fund our administrative and other operating expenses or our proposed research and development program for the next twelve months. In addition, we will require substantial new capital following the development of a strategic marketing plan for bringing our product to global markets in order to actually market, arrange for the manufacturing of, and sell our product. Because we do not expect to have any cash flow from operations within the next twelve months, we will need to raise additional capital, which may be in the form of loans from current stockholders and/or from public and private equity offerings. Our ability to access capital will depend on our success in implementing our business plan. It will also depend upon the status of the capital markets at the time such capital is sought. Without significant improvement in the capital markets, sufficient capital may not be available and the implementation of our business plan could be delayed. If we are unable to raise additional funds in the future, we may have to cease all substantive operations.

 

Item 1B.  Unresolved Staff Comments

 

None

 

Item 2.  Properties

 

.Our Offices are located at the Premises of the CEO c/o Efrat Schwartz 17 Harav Frank Street , Jerusalem , Israel , 96387

 

Item 3.  Legal Proceedings.

 

There are no pending legal proceedings to which the Company is a party or in which any Director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or security holder is a party adverse to the Company or has a material interest adverse to the Company. The Company’s property is not the subject of any pending legal proceedings.

 

PART II

 

Item 4. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Market Information

 

Our common stock has just been declared eligible to be traded on the Over-The-Counter Bulletin Board. ( Symbol BABA) however the stock is not currently trading

 

6
 

 

Holders

 

As of March 22, 2012, there were 5,500,000 common shares issued and outstanding, which were held by 42 stockholders of record.

 

Dividends

 

We have never declared or paid any cash dividends on our common stock nor do we anticipate paying any in the foreseeable future. Furthermore, we expect to retain any future earnings to finance our operations and expansion. The payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our earnings levels, capital requirements, any restrictive loan covenants and other factors the Board considers relevant.

 

Equity Compensation Plans

 

We do not have any equity compensation plans.

 

Recent Sales of Unregistered Securities; Use of Proceeds from Registered Securities

 

In January 2012 the Company issued 2,500,000 free trading shares pursuant to the effective S1 registration Statement declared effective by the SEC on January 9 2012 .

 

Purchases of Equity Securities by the Small Business Issuer and Affiliated Purchasers

 

We have not repurchased any shares of our common stock during the fiscal year ended December 31, 2011

 

Item 5. Selected Financial Data.

 

A smaller reporting company is not required to provide the information required by this item.

 

Item 6.   Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Certain statements contained in this Annual Report, including statements regarding the anticipated development and expansion of our business, our intent, belief or current expectations, primarily with respect to the future operating performance of  Baby All Corp and the services we expect to offer and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements. Future filings with the Securities and Exchange Commission, future press releases and future oral or written statements made by us or with our approval, which are not statements of historical fact, may contain forward-looking statements, because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

 

All forward-looking statements speak only as of the date on which they are made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made.

 

This Management’s Discussion and Analysis or Plan of Operations (“MD&A”) section of this Report discusses our results of operations, liquidity and financial condition, and certain factors that may affect our future results. You should read this MD&A in conjunction with our audited financial statements and accompanying notes included in this Report. This plan of operation contains forward-looking statements that involve risks, uncertainties, and assumptions. The actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those presented under “Risk Factors” or elsewhere in this Report.

 

7
 

 

Plan of Operation

 

Baby All’s infant medicine dispenser, which is a specially designed infant feeding-type bottle, allows parent and other care givers to administer liquid medications to infants in a more convenient and familiar structure. The design, development, manufacturing, and marketing of a commercial product will be carried out by 3 rd party partners who agree to license the design and pay a portion of future royalties to maintain the license on an ongoing basis.

 

As soon as the company starts to raise equity (following the S-1 becoming effective), it will begin to use raised proceeds to spearhead the marketing campaign needed to identify and come to exclusive agreements with one or more third party manufacturers.

 

THIRD-PARTY MANUFACTURERS

 

We will seek third parties to design, develop, manufacture, and market a product based on our design patent number 380828. These third party partners will enter into an agreement with Baby All to license the design and pay an upfront licensing fee and / or a portion of future royalties to maintain the license on an ongoing basis.

 

INTELLECTUAL PROPERTY

 

On December 13, 2010, we signed a Design Patent Transfer and Sale Agreement with Mrs. Julie Franchi, in relation to a design patent  (Design Patent number: 380828), licensing all rights, title and interest in, an infant medicine dispenser. The Patent was issued on September 1, 1998 and will expire on August 31, 2015. No other trademarks, licenses, franchises, concessions, royalty agreement s or labor contracts are in effect regarding this prospectus.

 

COMPETITION

 

While there are many medical dispensers on the market designed for infants, not all are designed to take into account the special needs of infants. Many are designed to prevent use by children, rather than focus on children as the potential patient needing medication. Many, like US Patent 5947329 (Medicine Dispenser), provide a method for dispensing medication in pill format, rather than liquid. The medicine dispenser described in this patent provides a challenge for children to gain access to the contents, while allowing relatively easy access to adults. It does not enable administering liquid medications to children or provide a method for measuring this liquid.

 

Other products currently available on the market include several devices shaped to please a child, but none are designed as our product. The market offerings include pacifier-type devices which would be strange for a child that is not accustomed to using a pacifier, or even, specifically, that type of pacifier. Further, there is a device shaped like an elephant. While this will entertain the child, it is not in a form to which the child is accustomed to seeing or putting in his or her mouth. Our product has the familiar shape and feel of a standard bottle and nipple, so even very young children are comfortable with the familiarity of the design. As we are interested in finding a third party partner to help us bring our product to the market, Baby All and its product do not yet have any position in the market.

 

US Patent 5620462 (Liquid vitamin and medicine dispenser for infants and toddlers) is for a liquid vitamin and medicine dispenser for infants and toddlers, comprising a flexible mask contoured to the shape of a mouth of an infant/toddler to provide support. A lock assembly is centrally mounted into the flexible mask. Unlike the Baby All design, this patent does not provide the same familiar experience as a standard bottle, thus we do not believe infants will adapt to the shape and design as easily as we expect they will adapt to our design. Furthermore, our design provides a removable cover that would make our infant medicine dispenser portable.

 

We are not aware of any products currently being sold in the market that prevent the administration of incorrect dosages of liquid medication to infants.  Our proposed product differs from products currently being sold in that it is designed to prevent the administration of incorrect dosages of liquid medicine.

 

Because we do not plan to design and manufacture a product based on our design patent, we cannot fully determine how a product would appear. We plan to license the existing design, which includes space for a corporate logo and branding elements but which could be combined with other patented or non-patented ideas to create a similar, but not identical product as compared to the design patent 380828.

 

Liquidity and Capital Resources

 

As of December 31, 2011 we had $300  in cash. We incurred a net loss of $33,570 for the fiscal year ended December 31, 2011 as compared with a net loss of $10,455  for the period December 31 2010.  Our cumulative net loss since inception is $44,025, which is comprised entirely of general and administrative expenses .

 

The Company does not believe that its cash resources will be sufficient to fund its expenses over the next 12 months. There can be no assurance that additional capital will be available to the Company. The Company currently has no agreements, arrangements, or understandings with any person to obtain funds through bank loans, lines of credit, or any other sources. Since the Company has no such arrangements or plans currently in effect, its inability to raise funds for the above purposes will have a severe negative impact on its ability to remain a viable company.

 

8
 

 

Lack of Insurance

 

The Company currently has no insurance in force for its office facilities and operations and it cannot be certain that it can cover the risks associated with such lack of insurance or that it will be able to obtain and/or maintain insurance to cover these risks at economically feasible premiums.

 

Going Concern Consideration

 

Our registered independent auditors have issued an opinion on our financial statements which includes a statement describing our going concern status. This means that there is substantial doubt that we can continue as an on-going business for the next 12 months unless we obtain additional capital to pay our bills and meet our other financial obligations. This is because we have not generated any revenues and no revenues are anticipated until we begin marketing the product. Accordingly, we must raise capital from sources other than the actual sale of the product. We must raise capital to implement our project and stay in business.

 

Recently issued accounting pronouncements

 

In March 2008, the FASB issued FASB Statement No. 161, (FASB ASC 815) “Disclosures about Derivative Instruments and Hedging Activities – an amendment of FASB Statement 133.”  SFAS No. 161 (FASB ASC 815) enhances required disclosures regarding derivatives and hedging activities, including enhanced disclosures regarding how:  (a) an entity uses derivative instruments; (b) derivative instruments and related hedged items are accounted for under FASB No. 133, “Accounting for Derivative Instruments and Hedging Activities”; and (c) derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows.  Specifically, SFAS No. 161 (FASB ASC 815) requires:

  

·disclosure of the objectives for using derivative instruments be disclosed in terms of underlying risk and accounting designation;
·disclosure of the fair values of derivative instruments and their gains and losses in a tabular format;
·disclosure of information about credit-risk-related contingent features;
·and cross-reference from the derivative footnote to other footnotes in which derivative-related information is disclosed.

 

SFAS No. 161 (FASB ASC 815) is effective for fiscal years and interim periods beginning after November 15, 2008.  Earlier application is encouraged.  The management of the Company does not expect the adoption of this pronouncement to have a material impact on its financial statements.

 

On May 9, 2008, the FASB issued FASB Statement No. 162, (FASB ASC 105) “The Hierarchy of Generally Accepted Accounting Principles.”  SFAS No. 162 (FASB ASC 105) is intended to improve financial reporting by identifying a consistent framework, or hierarchy, for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (“GAAP”) for nongovernmental entities.

 

Prior to the issuance of SFAS No. 162 (FASB ASC 105), GAAP hierarchy was defined in the American Institute of Certified Public Accountants (“AICPA”) Statement on Auditing Standards (“SAS”) No. 69, “The Meaning of Present Fairly in Conformity with Generally Accept Accounting Principles.”  SAS No. 69 has been criticized because it is directed to the auditor rather than the entity.  SFAS No. 162 (FASB ASC 105) addresses these issues by establishing that the GAAP hierarchy should be directed to entities because it is the entity (not the auditor) that is responsible for selecting accounting principles for financial statements that are presented in conformity with GAAP.

 

The sources of accounting principles that are generally accepted are categorized in descending order as follows:

 

  a. FASB Statements of Financial Accounting Standards and Interpretations, FASB Statement 133 Implementation Issues, FASB Staff Positions, and American Institute of Certified Public Accountants (AICPA) Accounting Research Bulletins and Accounting Principles Board Opinions that are not superseded by actions of the FASB.

 

  b. FASB Technical Bulletins and, if cleared by the FASB, AICPA Industry Audit and Accounting Guides and Statements of Position.

 

  c. AICPA Accounting Standards Executive Committee Practice Bulletins that have been cleared by the FASB, consensus positions of the FASB Emerging Issues Task Force (EITF), and the Topics discussed in Appendix D of EITF Abstracts (EITF D-Topics).

 

  d. Implementation guides (Q&As) published by the FASB staff, AICPA Accounting Interpretations, AICPA Industry Audit and Accounting Guides and Statements of Position not cleared by the FASB, and practices that are widely recognized and prevalent either generally or in the industry.

 

9
 

 

SFAS No. 162 (FASB ASC 105) is effective 60 days following the SEC’s approval of the Public Company Accounting Oversight Board amendment to its authoritative literature. It is only effective for nongovernmental entities; therefore, the GAAP hierarchy will remain in SAS 69 for state and local governmental entities and federal governmental entities. The management of the Company does not expect the adoption of this pronouncement to have a material impact on its financial statements.

 

On May 26, 2008, the FASB issued FASB Statement No. 163, (FASB ASC 944) “Accounting for Financial Guarantee Insurance Contracts.” SFAS No. 163 (FASB ASC 944) clarifies how FASB Statement No. 60, “Accounting and Reporting by Insurance Enterprises” (“SFAS No. 60”), applies to financial guarantee insurance contracts issued by insurance enterprises, including the recognition and measurement of premium revenue and claim liabilities. It also requires expanded disclosures about financial guarantee insurance contracts.

 

The accounting and disclosure requirements of SFAS No. 163 (FASB ASC 944) are intended to improve the comparability and quality of information provided to users of financial statements by creating consistency.  Diversity exists in practice in accounting for financial guarantee insurance contracts by insurance enterprises under SFAS No. 60, “Accounting and Reporting by Insurance Enterprises.”  That diversity results in inconsistencies in the recognition and measurement of claim liabilities because of differing views about when a loss has been incurred under FASB Statement No. 5, “Accounting for Contingencies” (“SFAS No. 5”).  SFAS No. 163 (FASB ASC 944) requires that an insurance enterprise recognize a claim liability prior to an event of default when there is evidence that credit deterioration has occurred in an insured financial obligation.  It also requires disclosure about (a) the risk-management activities used by an insurance enterprise to evaluate credit deterioration in its insured financial obligations and (b) the insurance enterprise’s surveillance or watch list.

 

SFAS No. 163 (FASB ASC 944) is effective for financial statements issued for fiscal years beginning after December 15, 2008, and all interim periods within those fiscal years, except for disclosures about the insurance enterprise’s risk-management activities.  Disclosures about the insurance enterprise’s risk-management activities are effective the first period beginning after issuance of SFAS No. 163 (FASB ASC 944).  Except for those disclosures, earlier application is not permitted.  The management of the Company does not expect the adoption of this pronouncement to have material impact on its financial statements.

 

On May 22, 2009, the FASB issued FASB Statement No. 164, (FASB ASC 958) “Not-for-Profit Entities: Mergers and Acquisitions”.  SFAS No. 164 (FASB ASC 958) is intended to improve the relevance, representational faithfulness, and comparability of the information that a not-for-profit entity provides in its financial reports about a combination with one or more other not-for-profit entities, businesses, or nonprofit activities.  To accomplish that, this Statement establishes principles and requirements for how a not-for-profit entity:

 

  a. Determines whether a combination is a merger or an acquisition.
  b. Applies the carryover method in accounting for a merger.
  c. Applies the acquisition method in accounting for an acquisition, including determining which of the combining entities is the acquirer.
  d. Determines what information to disclose to enable users of financial statements to evaluate the nature and financial effects of a merger or an acquisition.

 

This Statement also improves the information a not-for-profit entity provides about goodwill and other intangible assets after an acquisition by amending FASB Statement No. 142, Goodwill and Other Intangible Assets, to make it fully applicable to not-for-profit entities.

 

SFAS No. 164 (FASB ASC 958) is effective for mergers occurring on or after December 15, 2009, and acquisitions for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2009.  Early application is prohibited.  The management of the Company does not expect the adoption of this pronouncement to have material impact on its financial statements.

 

On May 28, 2009, the FASB issued FASB Statement No. 165, (FASB ASC 855) “Subsequent Events.”  SFAS No.  165 (FASB ASC 855) establishes general standards of accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued.  Specifically, Statement 165 (FASB ASC 855) provides:

 

  1. The period after the balance sheet date during which management of a reporting entity should evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements.
  2. The circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements.
  3. The disclosures that an entity should make about events or transactions that occurred after the balance sheet date.

 

In accordance with this Statement, an entity should apply the requirements to interim or annual financial periods ending after June 15, 2009.  The adoption of this pronouncement did not have a material impact on the financial statements of the Company.

 

In June 2009, the FASB issued FASB Statement No. 166, (FASB ASC 860) “Accounting for Transfers of Financial Assets- an amendment of FASB Statement No, 140.”  SFAS No. 166 (FASB ASC 860) is a revision to SFAS No. 140 “Accounting for Transfers and Servicing of Financial Assets and Extinguishment of Liabilities” and will require more information about transfers of financial assets, including securitization transactions, and where companies have continuing exposure to the risks related to transferred financial assets.  It eliminates the concept of a “qualifying special-purpose entity,” changes the requirements for derecognizing financial assets, and requires additional disclosures.

 

This statement is effective for financial asset transfers occurring after the beginning of an entity's first fiscal year that begins after November 15, 2009.  The management of the Company does not expect the adoption of this pronouncement to have material impact on its financial statements.

 

In June 2009, the FASB issued FASB Statement No. 167, (FASB ASC 810) "Amendments to FASB Interpretation No. 46(R).”  SFAS No. 167 (FASB ASC 810) amends certain requirements of FASB Interpretation No. 46(R), “Consolidation of Variable Interest Entities” and changes how a company determines when an entity that is insufficiently capitalized or is not controlled through voting (or similar rights) should be consolidated.  The determination of whether a company is required to consolidate an entity is based on, among other things, an entity’s purpose and design and a company’s ability to direct the activities of the entity that most significantly impact the entity’s economic performance.

 

This statement is effective as of the beginning of each reporting entity’s first annual reporting period that begins after November 15, 2009.  The management of the Company does not expect the adoption of this pronouncement to have material impact on its financial statements.

 

In June 2009, the FASB issued FASB Statement No. 168, (FASB ASC 105) "The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles - a replacement of FASB Statement No. 162.”  SFAS No. 168 (FASB ASC 105) establishes the FASB Accounting Standards Codification (the "Codification") to become the single official source of authoritative, nongovernmental U.S. generally accepted accounting principles (“GAAP”).  The Codification did not change GAAP but reorganizes the literature.

 

SFAS No. 168 (FASB ASC 105) is effective for interim and annual periods ending after September 15, 2009.  The adoption of this pronouncement did not have a material impact on the financial statements of the Company.

 

10
 

 

Off Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that are material to investors.

 

Item 6A.        Quantitative and Qualitative Disclosures About Market Risk.

 

A smaller reporting company is not required to provide the information required by this item.

 

11
 

 

Item 7. Financial Statements and Supplementary Data.

 

BABY ALL CORP.

(A DEVELOPMENT STAGE COMPANY)

 

INDEX TO FINANCIAL STATEMENTS

DECEMBER 31, 2011

 

Report of Registered Independent Auditors F-2
   
-Financial Statements  
   
Balance Sheets as of December 31, 2011 and December 31, 2010 F-3
   
Statements of Operations for the Years Ended December 31, 2011 and 2010, and Cumulative from Inception F-4
   
Statement of Changes in Stockholders’ Equity for the Period from Inception Through December 31, 2011 F-5
   
Statements of Cash Flows for the Years Ended December 31, 2011 and 2010 And Cumulative from Inception F-6
   
Notes to Financial Statements F-7

  

F-1
 

 

REPORT OF REGISTERED INDEPENDENT AUDITORS

 

To the Board of Directors and Stockholders

of Baby All Corp.:

 

We have audited the accompanying balance sheets of Baby All Corp. (a Delaware corporation in the development stage) as of December 31, 2011 and 2010, and the related statements of operations, stockholders’ equity, and cash flows for the periods ended December 31, 2011 and 2010, and from inception (November 30, 2010) through December 31, 2011. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

 

We conducted our audit in accordance with standards of the Public Company Accounting Oversight Board (United States of America). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

 

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Baby All Corp. as of December 31, 2011 and 2010, and the results of its operations and its cash flows for the periods ended December 31, 2011 and 2010, and from inception (November 30, 2010) through December 31, 2011, in conformity with accounting principles generally accepted in the United States of America.

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company is in the development stage, and has not established any source of revenue to cover its operating costs. As such, it has incurred an operating loss since inception. Further, as of December 31, 2011, the cash resources of the Company were insufficient to meet its planned business objectives. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plan regarding these matters is also described in Note 2 to the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Respectfully submitted,

Weinberg & Baer LLC

Baltimore, Maryland

January 18, 2012

 

F-2
 

 

BABY ALL CORP.

(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEET

AS OF DECEMBER 31, 2011 AND 2010

 

   As of   As of 
   December 31,   December 31, 
   2011   2010 
         
ASSETS 
           
Current Assets:          
Cash and cash equivalents  $300   $- 
Deferred offering costs   20,000    20,000 
           
Total current assets   20,300    20,000 
           
Total Assets  $20,300   $20,000 
           
LIABILITIES AND STOCKHOLDERS' (DEFICIT) 
           
Current Liabilities:          
Accounts payable and accrued liabilities  $41,125   $21,000 
Loans from related parties - Directors and stockholders   22,900    9,455 
           
Total current liabilities   64,025    30,455 
           
Total liabilities   64,025    30,455 
           
Commitments and Contingencies          
           
Stockholders' (Deficit):          
Common stock, par value $.0001 per share, 200,000,000 shares authorized; 3,000,000 shares issued and outstanding   300    300 
Stock subscription receivable   -    (300)
(Deficit) accumulated during the development stage   (44,025)   (10,455)
           
Total stockholders' (deficit)   (43,725)   (10,455)
           
Total Liabilities and Stockholders' (Deficit)  $20,300   $20,000 

 

The accompanying notes to financial statements

are an integral part of these financial statements.

 

F-3
 

 

BABY ALL CORP.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS

FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010

AND CUMULATIVE FROM INCEPTION (NOVEMBER 30, 2010)

THROUGH DECEMBER 31, 2011

 

   Year   Year     
   Ended   Ended   Cumulative 
   December 31,   December 31,   From 
   2011   2010   Inception 
             
Revenues  $-   $-   $- 
                
Expenses:               
Filing fees   6,600    -    6,600 
Professional fees   26,970    1,000    27,970 
Patent   -    7,500    7,500 
Legal - incorporation   -    1,955    1,955 
                
Total expenses   33,570    10,455    44,025 
                
(Loss) from Operations   (33,570)   (10,455)   (44,025)
                
Other Income (Expense)   -    -    - 
                
Provision for income taxes   -    -    - 
                
Net (Loss)  $(33,570)  $(10,455)  $(44,025)
                
(Loss) Per Common Share:               
(Loss) per common share - Basic and Diluted  $(0.01)  $(0.00)     
                
Weighted Average Number of Common Shares               
Outstanding - Basic and Diluted   3,000,000    3,000,000      

 

The accompanying notes to financial statements are

an integral part of these financial statements.

 

F-4
 

 

BABY ALL CORP.

(A DEVELOPMENT STAGE COMPANY)

STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

FOR THE PERIOD FROM INCEPTION (NOVEMBER 30, 2010)

THROUGH DECEMBER 31, 2011

 

               (Deficit)     
               Accumulated     
           Stock   During the     
   Common stock   Subscription   Development     
   Shares   Amount   Receivable   Stage   Totals 
                     
Balance - at inception   -   $-        $-   $- 
                          
Common stock issued for cash   3,000,000    300    (300)   -    - 
                          
Net (loss) for the period   -    -    -    (10,455)   (10,455)
                          
Balance - December 31, 2010   3,000,000   $300   $(300)  $(10,455)  $(10,455)
                          
Stock subscription payment received   -    -    300    -    300 
                          
Net (loss) for the period   -    -    -    (33,570)   (33,570)
                          
Balance - December 31, 2011   3,000,000   $300   $-   $(44,025)  $(43,725)

  

The accompanying notes to financial statements are

an integral part of these financial statements.

 

F-5
 

 

BABY ALL CORP.

(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOWS

FOR THE YEARS ENDED DECEMBER 31, 2011 AND 2010

AND CUMULATIVE FROM INCEPTION (NOVEMBER 30, 2010)

THROUGH DECEMBER 31, 2011

 

   Year   Year     
   Ended   Ended   Cumulative 
   December 31,   December 31,   From 
   2011   2010   Inception 
             
Operating Activities:               
Net (loss)  $(33,570)  $(10,455)  $(44,025)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:               
Changes in net assets and liabilities-               
Deferred offering costs   -    (20,000)   (20,000)
Accounts payable and accrued liabilities   20,125    21,000    41,125 
                
Net Cash Used in Operating Activities   (13,445)   (9,455)   (22,900)
                
Investing Activities:   -    -    - 
                
Net Cash Used in Investing Activities   -    -    - 
                
Financing Activities:               
Proceeds from stock issued   300    -    300 
Loans from related parties - directors and stockholders   13,445    9,455    22,900 
                
Net Cash Provided by Financing Activities   13,745    9,455    23,200 
                
Net (Decrease) Increase in Cash   300    -    300 
                
Cash - Beginning of Period   -    -    - 
                
Cash - End of Period  $300   $-   $300 
                
Supplemental Disclosure of Cash Flow Information:               
Cash paid during the period for:               
Interest  $-   $-   $- 
Income taxes  $-   $-   $- 

 

The accompanying notes to financial statements are

an integral part of these financial statements.

 

F-6
 

 

BABY ALL CORP.

(A DEVELOPMENT STAGE COMPANY)

NOTES TO FINANCIAL STATEMENTS

 

(1)  Summary of Significant Accounting Policies

 

Basis of Presentation and Organization

 

Baby All corp. (“Baby All” or the “Company”) is a Delaware corporation in the development stage and has not commenced operations. The Company was incorporated under the laws of the State of Delaware on November 30, 2010. The business plan of the Company is to seek third party entities interested in licensing the rights to manufacture and market the patent design of an “Infant medicine dispenser”. The accompanying financial statements of the Company were prepared from the accounts of the Company under the accrual basis of accounting.

 

Cash and Cash Equivalents 

 

For purposes of reporting within the statement of cash flows, the Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.

 

Revenue Recognition

 

The Company is in the development stage and has yet to realize revenues from operations. Once the Company has commenced operations, it will recognize revenues when delivery of goods or completion of services has occurred provided there is persuasive evidence of an agreement, acceptance has been approved by its customers, the fee is fixed or determinable based on the completion of stated terms and conditions, and collection of any related receivable is probable.

 

Loss per Common Share

 

Basic loss per share is computed by dividing the net loss attributable to the common stockholders by the weighted average number of shares of common stock outstanding during the period. Fully diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. There were no dilutive financial instruments issued or outstanding for the period ended December 31, 2011.

 

Income Taxes

 

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are determined based on temporary differences between the bases of certain assets and liabilities for income tax and financial reporting purposes. The deferred tax assets and liabilities are classified according to the financial statement classification of the assets and liabilities generating the differences.

 

The Company maintains a valuation allowance with respect to deferred tax assets. The Company establishes a valuation allowance based upon the potential likelihood of realizing the deferred tax asset and taking into consideration the Company’s financial position and results of operations for the current period. Future realization of the deferred tax benefit depends on the existence of sufficient taxable income within the carryforward period under the Federal tax laws.

 

Changes in circumstances, such as the Company generating taxable income, could cause a change in judgment about the realizability of the related deferred tax asset. Any change in the valuation allowance will be included in income in the year of the change in estimate.

 

F-7
 

 

Fair Value of Financial Instruments

 

The Company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts the Company could realize in a current market exchange. As of December 31, 2011, the carrying value of accrued liabilities, and loans from directors and stockholders approximated fair value due to the short-term nature and maturity of these instruments.

 

Deferred Offering Costs

 

The Company defers as other assets the direct incremental costs of raising capital until such time as the offering is completed. At the time of the completion of the offering, the costs are charged against the capital raised. Should the offering be terminated, deferred offering costs are charged to operations during the period in which the offering is terminated. 

 

Impairment of Long-Lived Assets

 

The Company evaluates the recoverability of long-lived assets and the related estimated remaining lives when events or circumstances lead management to believe that the carrying value of an asset may not be recoverable. For the period ended December 31, 2011, no events or circumstances occurred for which an evaluation of the recoverability of long-lived assets was required.

 

Common Stock Registration Expenses

 

The Company considers incremental costs and expenses related to the registration of equity securities with the SEC, whether by contractual arrangement as of a certain date or by demand, to be unrelated to original issuance transactions. As such, subsequent registration costs and expenses are expensed as incurred.

 

Estimates

 

The financial statements are prepared on the basis of accounting principles generally accepted in the United States. The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of December 31, 2011, and expenses for the period ended December 31, 2011, and cumulative from inception. Actual results could differ from those estimates made by management.

 

Fiscal Year End

 

The Company has adopted a fiscal year end of December 31.

 

Recent Accounting Pronouncements

 

In May 2011, the FASB issued ASU 2011-04, "Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and International Financial Reporting Standards ("IFRSs")." Under ASU 2011-04, the guidance amends certain accounting and disclosure requirements related to fair value measurements to ensure that fair value has the same meaning in U.S. GAAP and in IFRS and that their respective fair value measurement and disclosure requirements are the same. ASU 2011-04 is effective for public entities during interim and annual periods beginning after December 15, 2011. Early adoption is not permitted. The Company does not believe that the adoption of ASU 2011-04 will have a material impact on the Company's results of operation and financial condition.

 

In June 2011, the FASB issued ASU No. 2011-05, "Comprehensive Income (ASC Topic 220): Presentation of Comprehensive Income," ("ASU 2011-05") which amends current comprehensive income guidance. This accounting update eliminates the option to present the components of other comprehensive income as part of the statement of shareholders' equity. Instead, comprehensive income must be reported in either a single continuous statement of comprehensive income which contains two sections, net income and other comprehensive income, or in two separate but consecutive statements. ASU 2011-05 will be effective for public companies during the interim and annual periods beginning after Dec. 15, 2011 with early adoption permitted. The Company does not believe that the adoption of ASU 2011-05 will have a material impact on the Company's results of operation and financial condition.

 

F-8
 

 

There were various other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries.  None of the updates are expected to a have a material impact on the Company's financial position, results of operations or cash flows.

 

(2)  Development Stage Activities and Going Concern

 

The Company is currently in the development stage, and has no operations. The business plan of the Company is to seek third party entities interested in licensing the rights to manufacture and market the patent design of an “Infant medicine dispenser”.

 

On December 13, 2010, the Company entered into a Patent Transfer and Sale Agreement whereby the Company acquired all of the right, title and interest in the patent known as the “Infant medicine dispenser” for consideration of $7,500 including attorney's fees. The United States Design Patent number is 380828.  

 

The Company has commenced a capital formation activity by filing a Registration Statement on Form S-1 to the SEC to register and sell in a self-directed offering 2,500,000 shares of newly issued common stock at an offering price of $0.03 per share for proceeds of up to $75,000. As of December 31, 2011, the Company accrued $20,000 of deferred legal and accounting offering costs related to this capital formation activity. The Registration Statement was declared effective on January 9, 2012.

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has not established any source of revenue to cover its operating costs, and as such, has incurred an operating loss since inception. Further, as of December 31, 2011, the cash resources of the Company were insufficient to meet its current business plan, and the Company had negative working capital. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

 

(3)  Patent

 

On December 13, 2010, the Company entered into a Patent Transfer and Sale Agreement whereby the Company acquired all of the right, title and interest in the patent known as the “Infant medicine dispenser” for consideration of $7,500 including attorney's fees. The United States Design Patent number is 380828. Under the terms of the Patent Transfer and Sale Agreement, the Company was assigned rights to the patent free of any liens, claims, royalties, licenses, security interests or other encumbrances. The cost of obtaining the patent was expensed.

 

(4)  Loans from Related Parties - Directors and Stockholders

 

As of December 31, 2011, loans from related parties amounted to $22,900 and represented working capital advances from Directors who are also stockholders of the Company. The loans are unsecured, non-interest bearing, and due on demand. 

 

(5)  Common Stock

 

On December 1, 2010, the Company issued 3,000,000 shares of its common stock to individuals who are Directors and officers of the company for $300. The Company received payment of the receivable in January 2011.

 

F-9
 

 

The Company has commenced a capital formation activity by filing a Registration Statement on Form S-1 to the SEC to register and sell in a self-directed offering 2,500,000 shares of newly issued common stock at an offering price of $0.03 per share for proceeds of up to $75,000. As of December 31, 2011, the Company accrued $20,000 of deferred legal and accounting offering costs related to this capital formation activity. The Registration Statement was declared effective on January 9, 2012.

 

(6)  Income Taxes

 

The provision (benefit) for income taxes for the periods ended December 31, 2011 and 2010, was as follows (assuming a 23% effective tax rate)

 

   2011   2010 
         
Current Tax Provision:          
Federal-          
Taxable income  $-   $- 
           
Total current tax provision  $-   $- 
           
Deferred Tax Provision:          
Federal-          
Loss carryforwards  $7,836   $689 
Change in valuation allowance   (7,836)   (689)
           
Total deferred tax provision  $-   $- 

  

The Company had deferred income tax assets as of December 31, 2011 and 2010, as follows:

 

   2011   2010 
         
Loss carryforwards  $8,525   $689 
Less - Valuation allowance   (8,525)   (689)
           
Total net deferred tax assets  $-   $- 

 

The Company provided a valuation allowance equal to the deferred income tax assets for the periods ended December 31, 2011 and 2010, because it is not presently known whether future taxable income will be sufficient to utilize the loss carryforwards.

 

As of December 31, 2011, the Company had approximately $37,000 in tax loss carryforwards that can be utilized in future periods to reduce taxable income, and expire by the year 2031.

 

The Company did not identify any material uncertain tax positions.  The Company did not recognize any interest or penalties for unrecognized tax benefits.

 

The Company will file income tax returns in the United States. All tax years are closed by expiration of the statute of limitations.

 

(7)  Related Party Transactions

 

As described in Note 4, as of December 31, 2011, the Company owed $22,900 to Directors, officers, and principal stockholders of the Company for working capital loans.

 

As described in Note 5, on December 1, 2010, the Company issued 3,000,000 shares of its common stock to Directors and officers for $300 receivable. The Company received payment of the receivable in January 2011.

 

F-10
 

 

Item 8.           Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 8A(T).   Controls and Procedures.

 

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

We are required to maintain disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our CEO and Internal Accounting Officer , to allow timely decisions regarding required disclosure. As of December 31 2011 we conducted an evaluation, under the supervision, and with the participation of our CEO and INTERNAL ACCOUNTING OFFICER , of the effectiveness of the design and operation of our disclosure controls and procedures. Based on this evaluation, our CEO and INTERNAL ACCOUNTING OFFICER concluded that our disclosure controls and procedures were effective.

 

Management does not expect that our Disclosure Controls and internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management or board override of the control.

 

The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934 as a process designed by, or under the supervision of, the company's CEO and INTERNAL ACCOUNTING OFFICER and effected by the company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

 

  * Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;

 

  * Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

 

12
 

 

  * Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company's assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

 

As of December 31 2011 management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, during the period covered by this report, such internal controls and procedures were effective .

 

Attestation report of the registered public accounting firm

 

This annual report does not include an attestation report of the Company's registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by the Company's registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the company to provide only management's report in this annual report.

 

Changes in internal control over financial reporting

 

During the year ended December 31, 2011, there was no change in our internal control over financial reporting that has materially affected, or is reasonably likely to materially affect our internal control over financial reporting.

 

Item 8B.        Other Information.

 

On January 9, 2012 the SEC declared the S1 of the Company effective to register 2,500,000 shares of its common stock and to raise gross proceeds of $75,000 from the issuance of the shares.

 

Subsequent to December 31 2011 the Company raised gross proceeds of $75,000 from the issuance of 2,500,000 common shares pursuant to the effective S1 registration statement declared effective on January 9 2012

 

13
 

 

PART III

 

Item 9.           Directors, Executive Officers and Corporate Governance.

 

Directors and Executive Officers

  

Our Directors hold office until the next annual meeting of our stockholders or until their successors is duly elected and qualified. Set forth below is a summary description of the principal occupation and business experience of each of our Directors and executive officers for at least the last five years.

  

Efrat Schwartz has been our President and Director since the Company's inception on November 30, 2010.

 

Mrs Schwartz obtained her degree in Educational Management at Machon Herzog in Petach Tikvah in August 2004.  She completed her coursework for a master’s degree in Biblical Science and History at the Bar Ilan University in Tel Aviv in September 2006, but she has not been awarded a master’s degree, pending completion of her thesis. From January 2006 until January 2007 she concurrently worked as an administrative assistant at the College Midreshet Moriah and at  University College in Tel Aviv.  From January 2007 until present she has worked  as Head of Administration at the University Yeshurun in Petach Tikvah.

 

The Board believes that Mrs Schwartz should serve as a Director and Chief Executive Officer due to her management and administrative skills all of which enable her to provide oversight and direction of the Company including overseeing its business operations and bringing the Company to its objective goals.

 

Merav Shalom has been our Secretary, Director and Principal Accounting and Financial Officer since the Company's inception .

 

Merav Shalom studied at Michlelet Hishuvim between the years from September 2005 until August 2008, and obtained a degree in finance. From October 2008 until January 2010 Mrs Shalom worked as account manager at Lev Ofir Group in Jerusalem, an electrical Company that markets and sells electrical communication appliances. From January 2010 until present she has worked  at Bet Haaracha, a Jerusalem-based hotel, as a controller.

 

The Board believes that Mrs Shalom should serve as a Director and as an accounting and Finance Officer due to her accounting and finance knowledge and administrative skills all of which enable her to provide oversight and direction of the Company including overseeing all the financial aspects of the Company.

 

14
 

 

There are no familial relationships among any of our directors or officers. None of our directors or officers is a director in any other U.S. reporting companies. None of our directors or officers has been affiliated with any company that has filed for bankruptcy within the last five years. The Company is not aware of any proceedings to which any of the Company’s officers or directors, or any associate of any such officer or director, is a party adverse to the Company or any of the Company’s subsidiaries or has a material interest adverse to it or any of its subsidiaries.

 

Each director of the Company serves for a term of one year or until the successor is elected at the Company's annual shareholders' meeting and is qualified, subject to removal by the Company's shareholders. Each officer serves, at the pleasure of the Board of Directors, for a term of one year and until the successor is elected at the annual meeting of the Board of Directors and is qualified.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

Section 16(a) of the Securities Exchange Act of 1934 requires officers and directors of the Company and persons who own more than ten percent of a registered class of the Company's equity securities to file reports of ownership and changes in their ownership with the Securities and Exchange Commission, and forward copies of such filings to the Company. We believe, based solely on our review of the copies of such forms, that during the fiscal year ended December 31, 2011, all reporting persons complied with all applicable Section 16(a) filing requirements.

 

Auditors

 

Weinberg and Baer  CPA , an independent registered public accounting firm, is our auditor.

 

We do not currently have a Code of Ethics applicable to our principal executive, financial and accounting officers. We do not have a “financial expert” on the board or an audit committee or nominating committee.

 

Potential Conflicts of Interest

 

Since we do not have an audit or compensation committee comprised of independent directors, the functions that would have been performed by such committees are performed by our directors. The Board of Directors has not established an audit committee and does not have an audit committee financial expert, nor has the Board established a nominating committee. The Board is of the opinion that such committees are not necessary since the Company has only two directors, and to date, such directors have been performing the functions of such committees. Thus, there is a potential conflict of interest in that our directors and officers have the authority to determine issues concerning management compensation, nominations, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our executive officers or directors.

 

Involvement in Certain Legal Proceedings

 

There are no legal proceedings that have occurred within the past five years concerning our directors, or control persons which involved a criminal conviction, a criminal proceeding, an administrative or civil proceeding limiting one's participation in the securities or banking industries, or a finding of securities or commodities law violations.

 

15
 

 

 

Item 10.Executive Compensation.

 

Summary Compensation

 

Since our incorporation , we have  not paid any compensation to any of  our Directors  in consideration for their services rendered to our Company in their capacity as such.  We have no employment agreements with any of our Directors or executive officers.  We have no pension, health, annuity, bonus, insurance, stock options, profit sharing or similar benefit plans.

 

Since our incorporation , no stock options or stock appreciation rights were granted to any of our Directors or executive officers.  We have no long-term equity incentive plans.

 

Outstanding Equity Awards

 

None of our Directors or executive officers holds unexercised options, stock that has not vested, or equity incentive plan awards.

 

Compensation of Directors

 

Since our incorporation , no compensation has been paid to any of our Directors other than mentioned above  in consideration for their services rendered in their capacity as directors.

 

Item 11.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table lists, as of March 22 ,2012, the number of shares of common stock of our Company that are beneficially owned by (i) each person or entity known to our Company to be the beneficial owner of more than 5% of the outstanding common stock; (ii) each officer and director of our Company; and (iii) all officers and directors as a group. Information relating to beneficial ownership of common stock by our principal shareholders and management is based upon information furnished by each person using “beneficial ownership” concepts under the rules of the Securities and Exchange Commission. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or direct the voting of the security, or investment power, which includes the power to vote or direct the voting of the security. The person is also deemed to be a beneficial owner of any security of which that person has a right to acquire beneficial ownership within 60 days. Under the Securities and Exchange Commission rules, more than one person may be deemed to be a beneficial owner of the same securities, and a person may be deemed to be a beneficial owner of securities as to which he or she may not have any pecuniary beneficial interest. Except as noted below, each person has sole voting and investment power.

 

The percentages below are calculated based on 5,500,000 shares of our common stock issued and outstanding as of March 22 , 2012 . We do not have any outstanding options, warrants or other securities exercisable for or convertible into shares of our common stock.

 

16
 

 

Name and Address of
Beneficial Owner
  Number of Shares of Common
Stock Beneficially
Owned or Right to
Direct Vote  (1)
   Percent of
Common
Stock Beneficially
Owned or Right
to Direct Vote
 
Efrat Schwartz   1,500,000    27%
Merav Shalom   1,500,000    27%

 

(1) Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission (the "SEC") and generally includes voting or investment power with respect to securities. In accordance with SEC rules, shares of common stock issuable upon the exercise of options or warrants which are currently exercisable or which become exercisable within 60 days following the date of the information in this table are deemed to be beneficially owned by, and outstanding with respect to, the holder of such option or warrant. Except as indicated by footnote, and subject to community property laws where applicable, to our knowledge, each person listed is believed to have sole voting and investment power with respect to all shares of common stock owned by such person.

 

Item 12.Certain Relationships and Related Transactions, and Director Independence.

 

Other than the transactions discussed below, we have not entered into any transaction nor are there any proposed transactions in which our Director, executive officer, stockholders, or any member of the immediate family of the foregoing had or is to have a direct or indirect material interest.

 

As of December 31, 2011, the Company owed $22,900 to Directors, officers, and principal stockholders of the Company for working capital loans.

 

On December 1, 2010, the Company issued 3,000,000 shares of its common stock to Directors and officers for $300 receivable. The Company received payment of the receivable in January 2011. 

 

17
 

 

Director Independence

 

We are not subject to listing requirements of any national securities exchange or national securities association and, as a result, we are not at this time required to have our board comprised of a majority of “independent directors.” We do not believe that any of our directors currently meet the definition of “independent” as promulgated by the rules and regulations of the American Stock Exchange.

 

Item 13.Principal Accounting Fees and Services.

 

Our principal independent accountant is Weinberg and Bear LLC. Their pre-approved fees billed to the Company are set forth below:

 

   For Fiscal Year Ended
December 31, 2011
   For Fiscal Year Ended
December 31, 2010
 
Audit Fees  $11,000   $10,000 
           
Tax Fees ( Paid to Alan Weinberg CPA )  $500   $500 

 

As of December 31, 2011, the Company did not have a formal documented pre-approval policy for the fees of the principal accountant. The Company does not have an audit committee. The percentage of hours expended on the principal accountant's engagement to audit our financial statements for the most recent fiscal year that were attributed to work performed by persons other than the principal accountant's full-time, permanent employees was 0%.

 

PART IV

 

Item 14.Exhibits and Financial Statement Schedules.

 

Exhibit   Description
     
Exhibit    
     
3.1   Articles of Incorporation of the Company (filed as Exhibit 3.1 to Registration Statement on Form S1, filed with the Securities and Exchange Commission on January 9, 2012 )
3.2   Bylaws of the Company (filed as Exhibit 3.2 to Registration Statement on Form S1, filed with the Securities and Exchange Commission on January 9 , 2012 )
3.3   Form of Common Stock Certificate of the Company (filed as Exhibit 3.3 to Registration Statement on Form S1, filed with the Securities and Exchange Commission on January 9 , 2012 )
10.1   Patent Assignment Agreement  (filed as Exhibit 10.1 to Registration Statement on Form S1, filed with the Securities and Exchange Commission on  January 9 , 2012 )
     
31.1   Certification of Principal Executive  Officer Pursuant to Exchange Act Rule 13A-14(A)/15D-14(A) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2   Certification of Principal  Accounting Officer Pursuant to Exchange Act Rule 13A-14(A)/15D-14(A) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1   Certification of Principal Executive  Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002(filed herewith)
     
32.2   Certification of Principal Accounting Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002(filed  herewith)

 

18
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Baby All Corp    
         
Date: March 22 ,2012   By: /s/ Efrat Schwartz  
    Name:    
    Title: Chief Executive Officer,  and Director
         
    By ; /s/ Merav Shalom  
    Name :    
    Title : Principal Accounting and Financial Officer , and Secretary  

 

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Date: March 22 ,2012   By: /s/ Efrat Schwartz  
    Name:    
    Title: Chief Executive Officer, and Director  
         
Date: March 22 , 2012   By: /s/ Merav Shalom  
    Name:    
    Title: Principal Accounting and Financial Officer , and  Secretary

 

19